Hoff FW, Yocum AO, Borate UM, et al. Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML. Blood Neoplasia. 2025;2(3):100125
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research · Retinoids in leukemia and cellular processes · Acute Lymphoblastic Leukemia research
On page 3, the colors in the legends for Figure 2A-F are transposed. Blue should correspond to the mutated cases, and red should represent wild type. The corrected Figure 2A-F is shown below.Figure 2.Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.